OliX, Icure IPOs Test Korean Biotech Sentiment Amid Samsung Uncertainties
Executive Summary
OliX Pharmaceuticals and Icure are poised to be first biotech firms to launch IPOs this year amid uncertainties over ongoing accounting issues at Samsung BioLogics and possible tougher accounting reviews on IPO seekers.
You may also be interested in...
Korea To Examine Companies' R&D-Related Accounting For Transparency
In a move to harmonize the pharma and biotech industry's accounting practices with global trends, South Korea’s financial authority will examine companies’ R&D cost-related accounting to check for possible ‘distortions’.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.